Bristol-Myers Squibb entered a collaboration with Duke University’s Clinical Research Institute (DCRI) to expand access to certain clinical trial information for independent scientific review through DCRI. This collaboration is one of a series of initiatives by BMS to support data sharing and disclosure of clinical trial information for scientific research and will include protocols, full clinical study reports (CSR) and de-identified patient-level data and study-level data for drugs and indications approved in the U.S. and/or Europe.
“Bristol-Myers Squibb’s collaboration with DCRI reflects our commitment to providing broader, more timely access to important clinical trial information and serves as a catalyst to strengthening public confidence in medicines, advancing science and improving public health,” said Francis Cuss, executive vice president and chief scientific officer, BMS.
“This program is a great leap forward for open science and is highly consistent with the DCRI’s mission to develop and share knowledge that improves the care of patients around the world through innovative clinical research,” said Dr. Eric Peterson, executive director of the DCRI.
BMS, DCRI in Clinical Data Access Alliance
Published June 24, 2014
Related Breaking News
Related Online Exclusives